Skip to main content
Premium Trial:

Request an Annual Quote

Sorcerer Enterprise, ActiveStor, Phenyx, Marvin & JChem 5.1, ProteoIQ 1.1, AurScope Global Pharmacology Space, AurProfiler, Cancer Molecular Analysis Portal

Premium
Thermo Fisher Scientific and Sage-N Research have launched Sorcerer Enterprise, a new version of the accelerated Sorcerer proteomics software platform designed for the enterprise Linux market.
 
Sorcerer Enterprise allows users to perform proteomic analyses on high-performance Linux systems, including blade servers and conventional Linux clusters.
 
It can be used as a standalone data analysis system to support hundreds of proteomics researchers using a web interface or it can interface with Thermo’s Windows-based Proteome Discoverer software.
 

 
Panasas said that it has expanded its ActiveStor product line to increase performance and storage capabilities and to include a new second-tier parallel storage solution. According to the company, the new solution halves storage space, power use, cooling, and floor space.
 
Panasas said that the National Center for Biotechnology Information is using its parallel storage products for its work on the 1000 Genomes Project.
 
The new ActiveStor product family includes the ActiveStor 6000, which includes 20 GB cache per storage shelf with an integrated 10GigE switch that doubles the throughput performance per storage shelf to over 600 MB/s; ActiveStor 4000 parallel storage clusters with an integrated 10GigE switch; and the new ActiveStor 200, which the company said is the industry's first parallel second-tier storage solution. The ActiveStor 200 includes 104 TB of available storage space, 5-gigabit Ethernet ports for data transfer, and proprietary tiered parity data protection.
 

 
Geneva Bioinformatics has launched Phenyx 2.6. Improvements in the latest version of the proteomics analysis software, developed in collaboration with the Swiss Institute of Bioinformatics, include support of the “major” labeling technologies and label-free approaches; analysis of simple to complex quantitation workflows; support of international standards such as MCP/MIAPE exports and mzML format; enhanced validation through a false discovery rate estimation functionality and statistical reports on the calibration status of the MS instrument; a new algorithm for extended post-translational modification discovery, expanded integration with third-party software, and an enhanced database manager to install and update multiple public and proprietary sequence databases.
 

 
ChemAxon, a cheminformatics provider based in Budapest, Hungary, has launched version 5.1 of its cheminformatics toolkits, Marvin and JChem.
 
Among the improvements are the introduction of IUPAC name import and support for OLE 2 format helping researchers to integrate the tool with Microsoft Office applications. The IUPAC Naming Calculator Plugin allows batches of chemical names to be stored as structures and found during chemical search.
 
OLE 2 extends interoperability with Microsoft Office applications and JavaScript support for ChemAxon's structure based calculation language, Chemical Terms. The JavaScript support can enable dynamic interaction between the Chemical Terms calculation and the drawn chemical structure, even during structure editing.
 

 
Bioinquire has released ProteoIQ 1.1. Theproteomics bioinformatics suite allows users to customize how tandem mass spectra are displayed, including annotation of ion series labels, charge states, and enhanced screening functionality for identifying neutral losses.
 
It also allows researchers to export annotated MS/MS spectra for identified peptides and save proteomic results in a format that conforms with the Paris Guidelines for the Reporting of Protein Identification Data
 

 
Aureus Pharma of Paris, France, has released three new AurScope databases. The new offerings include knowledge databases for nuclear receptors and proteases, as well as the centralized product AurScope Global Pharmacology Space, or AurSCOPE GPS, which, according to the company, includes all of “pharmaceutically important” therapeutic targets including G-protein coupled receptors , kinases, ion channels, nuclear receptors, and proteases.
 
The company also released AurProfiler, software that helps researchers evaluate target, cell, and drug profiles using bio-assays derived from the activity data found in the AurScope databases. AurProfiler was developed in collaboration with a pharmaceutical industry focus group consisting of several undisclosed major pharmaceutical companies.
 

 
The National Cancer Institute’s Cancer Biomedical Informatics Grid project has launched a beta version of the Cancer Molecular Analysis Portal. The portal includes a data set generated from the Cancer Genome Atlas Project on the brain tumor glioblastoma multiforme.  
 
The portal offers scientists an interface through which they can integrate, visualize, and explore clinical and genomic characterization data from translational research studies, such as the NCI’s Cancer Genome Atlas pilot project and NCI’s REMBRANDT, the Repository of Molecular Brain Neoplasia Data, which will be added by the end of 2008.
 
The current version of the CMA portal provides web access to tools to analyze and visualize gene expression, gene copy number, SNP and methylation data, and DNA sequence. Scientists can frame data in the context of clinical information, including treatment history, pathology status, tumor site, and surgical history.
 
The NCI said in a statement that enhancements and refinements to the CMA Portal are ongoing and that in the future it will include data from other cancer projects as well as additional functionality and improved analytical tools.
 
TCGA data can be analyzed using GenePattern, principal component analysis, and the Cancer Genome Workbench analysis tools via the CMA. It also can be accessed through the TCGA Data Portal, which provides advanced tools for selecting subsets of data for download. Lung and ovarian tumor data will be made available as they are generated by the TCGA project, NCI said.

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.